F-10: Cybin Files $1 Billion Shelf Prospectus to Fund Psychedelic Drug Development

Cybin Inc. has filed a preliminary base shelf prospectus to offer up to $1 billion in various securities, aiming to secure future funding for its clinical-stage psychedelic therapeutics pipeline targeting mental health conditions.

Summary

• Filed a preliminary base shelf prospectus to offer up to $1,000,000,000 in common shares, warrants, units, debt securities, and subscription receipts over a 25-month period.
• The company is a clinical-stage neuropsychiatry company focused on developing psychedelic therapeutics for mental health conditions.
• Current research and development focuses on structural modifications of known tryptamine and phenethylamine derivatives to improve pharmacokinetic properties.
• Key programs include CYB003 (a deuterated psilocin molecule) and CYB004 (a deuterated version of DMT).
• Received UK Medical and Healthcare Products Regulatory Agency (MHRA) approval to commence EMBRACE, the second pivotal Phase 3 study for CYB003.
• Anticipates requiring approximately $139,130,000 to continue operations over the next 12 months.
• Cash position as of July 30, 2025, was approximately $147,907,894.
• Has raised approximately $514,000,000 in gross proceeds through private placement and prospectus offerings since inception.
• Common Shares are listed on Cboe Canada Inc. (CYBN) and NYSE American LLC (CYBN), with closing prices on July 30, 2025, of $10.10 (Cboe Canada) and US$7.30 (NYSE American).

Sentiment

Score: 6

Explanation: The filing of a shelf prospectus is a proactive step to ensure future funding, which is positive for a clinical-stage company with significant R&D expenses and no current revenue. The UK MHRA approval for a Phase 3 study is a strong positive. However, the company remains pre-revenue, has negative cash flow, and faces substantial regulatory and development risks inherent in the psychedelic therapeutics industry, balancing the overall sentiment to moderately positive due to the enabled financial flexibility.

Positives

• Secures ability to raise up to $1,000,000,000 in capital over 25 months, providing significant financial flexibility for future operations and research and development.
• Received UK MHRA approval to commence EMBRACE, the second pivotal Phase 3 study for CYB003, advancing its lead program.
• Maintains a strong cash position of approximately $147,907,894 as of July 30, 2025, which is sufficient to fund operations for the next 12 months.
• Combined development portfolios with Small Pharma Inc. are highly complementary, offering operational and cost synergies.
• Holds over 90 granted patents and over 230 pending applications, indicating a robust intellectual property strategy.

Negatives

• Has experienced operating losses and negative cash flow from operations since inception.
• Currently has no products approved by Health Canada, the FDA, or any similar regulatory authority.
• Success is dependent on the ability to finance cash requirements, with no assurance that additional capital will be available on favorable terms or at all.
• Drug development is very expensive and involves long lead times and many variables of uncertainty.
• No assurance that research and development programs will result in regulatory approval or commercially viable products.
• No assurance that anticipated timelines for clinical trials will be met or that studies will be completed.
• The company has no history of paying cash dividends and does not anticipate doing so in the near future.

Risks

• **Regulatory Risks and Uncertainties**: Psychedelic drugs are classified as controlled substances (Schedule III in Canada, Schedule I in US, Class A/Schedule 1 in UK, List 1 in Netherlands), making medical and recreational use illegal without specific approvals, and there is no guarantee of approval as medicines.
• **Loss of Licenses and Permits**: The loss of necessary licenses and permits for scheduled drugs could have an adverse effect on operations.
• **Industry Evolution**: The psychedelic drug industry is new, and the impact of evolving compliance regimes is unpredictable.
• **Controlled Substances Law Reform**: Business success is dependent on favorable reform of controlled substances laws; if not reformed, commercial opportunity may be highly limited.
• **Unproven Efficacy**: Claims regarding psychedelic compounds have not been evaluated by regulatory authorities, and efficacy has not been confirmed by approved research; vigorous scientific research and clinical trials are needed.
• **"Foreign Private Issuer" Status**: As a foreign private issuer under U.S. securities laws, the company is subject to different, less frequent reporting obligations than U.S. domestic issuers, and officers/directors are exempt from certain reporting provisions.
• **Speculative Investment**: Investment is highly speculative due to the risky nature of the business and early stage of development; investors may lose their entire investment.
• **Negative Operating Cash Flow**: Continuous negative cash flow requires ongoing financing, with no assurance of availability or favorable terms.
• **Discretion over Use of Proceeds**: Management has broad discretion over the use of proceeds from offerings, which may vary from proposed uses.
• **Need for Additional Financing**: Future operations require additional capital, which may lead to dilution for existing shareholders.
• **Volatile Market Price**: Share price is subject to high volatility, potentially unrelated to operating performance, and influenced by factors like regulatory changes, competition, and additional share sales.
• **Potential Dilution**: Future issuances of common shares or other securities, including up to 20,000,000 common shares from convertible debentures, could substantially dilute voting power and earnings per share.
• **Limited Market for Unlisted Securities**: No established market for Subscription Receipts, Warrants, Units, and Debt Securities, affecting pricing, transparency, liquidity, and issuer regulation.
• **Enforcement of Civil Liabilities**: Difficulty for investors to enforce judgments against the company or its non-U.S. resident officers/directors due to Canadian incorporation and assets/personnel outside the U.S.

Future Outlook

The company plans to continue its research and development of next-generation neuropsychiatry therapeutics, evaluating novel synthetic psychedelic active pharmaceutical ingredients and innovative drug delivery systems. It intends to apply for regulatory approval for therapies targeting major depressive disorder, alcohol use disorder, generalized anxiety disorder, and other mental health conditions. Over the next 12 months, the company will seek strategic partnerships to advance scientific research and intellectual property for new psychedelic-based compounds and delivery mechanisms, and will sponsor clinical trials to advance understanding of safety and efficacy.

Management Comments

• Management believes forward-looking statements provide useful information to readers when considering investment objectives, but cautions that actual results may differ materially due to various risks and uncertainties.
• Management has broad discretion in the application of proceeds of an Offering of Securities.

Industry Context

The filing highlights Cybin's position as a clinical-stage company in the nascent psychedelic therapeutics industry, which focuses on developing novel treatments for mental health conditions. This sector is characterized by extensive research and development, long lead times, high costs, and significant regulatory hurdles, as psychedelic substances are largely controlled globally. The company's strategy aligns with the broader industry trend of exploring new pharmacological approaches and delivery methods to address unmet needs in mental healthcare, differentiating itself through structural modifications of known compounds and diverse administration routes (inhalation, intravenous, intramuscular, subcutaneous).

Stakeholder Impact

• **Shareholders**: Potential for significant dilution from future capital raises (up to $1 billion shelf, 20M shares from convertible debentures). Reliance on capital appreciation for return on investment as no dividends are anticipated. High speculative risk.
• **Employees**: Potential for reduction in workforce and/or compensation if sufficient capital is not raised.
• **Customers (Future Patients)**: Potential for new treatment options for mental health conditions if drug development is successful.
• **Creditors**: The company's ability to meet obligations is contingent on successful additional financing.
• **Suppliers/Partners**: Continued engagement with third-party researchers, suppliers, and manufacturers for R&D activities.

Next Steps

• Initiate the second Phase 3 study, EMBRACE, for CYB003 (around mid-year 2025).
• Progress Phase 3 APPROACH studies in MDD for CYB003 (expected 2026).
• Complete the Phase 2 GAD study for CYB004 (around mid-year 2025).
• Complete preclinical development of phenethylamine drug candidate (Q1 2026).
• Continue to seek strategic partnerships to advance scientific research and intellectual property for new psychedelic-based compounds and novel delivery mechanisms.
• Continue to sponsor select internal and partner-related clinical trials.
• Annual and special meeting of shareholders to be held on August 18, 2025.
• Transfer any ongoing (approved) trials under the Clinical Trials Directive to CTIS by January 2025 (EU requirement).
• New UK clinical trials legislation (Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2024) to come into effect from mid-April 2026.

Key Dates

Recommendation

Cybin Inc. is an early-stage biotechnology company operating in the high-risk, high-reward psychedelic therapeutics space. The filing of a $1 billion shelf prospectus provides crucial financial flexibility for its extensive R&D pipeline, including the advancement of its lead CYB003 program into Phase 3 studies, which is a positive step. However, the company has a history of operating losses, no approved products, and faces significant regulatory and commercialization challenges. The potential for substantial future dilution from capital raises, as highlighted by the convertible debentures and the shelf offering, presents a notable risk to existing shareholders. Given the speculative nature of drug development and the long path to profitability, a 'hold' recommendation is appropriate for investors who are already exposed to the stock and are comfortable with high risk, allowing them to monitor clinical trial progress and capital deployment. New investors should approach with extreme caution due to the inherent uncertainties and risks.

Keywords

Psychedelic Therapeutics, Mental Health, Drug Development, Clinical Stage, SEC Filing, Shelf Prospectus, CYB003, CYB004, Psilocin, DMT, Biotechnology, Pharmaceutical, Capital Raise, Neuropsychiatry, Clinical Trials, Regulatory Approval, Intellectual Property, CYBN